https://www.selleckchem.com/pr....oducts/Gefitinib.htm
However, the hazard ratio (95% CI) for mortality was substantially greater among pharmacologic patients 2.39 (1.83-3.1. For each level of CAC abnormality, pharmacologic patients had 2-fold increased risk adjusted hazard ratio for all-mortality risk (p0.05 for each CAC level). Among propensity-matched exercise versus pharmacologic patients, the same findings were observed. Among patients referred for stress-rest SPECT-MPI and CAC scoring, pharmacologic patients have substantially increased mortality risk compared to exercise